Divi's Laboratories (DIVISLAB) — Financial Results

Divi's Laboratories reported consolidated total income of ₹2,671 crores in Q4 FY25, up from ₹2,382 crores YoY, with PAT rising to ₹662 crores from ₹538 crores. Full-year total income reached ₹9,712 crores, up from ₹8,184 crores, and PAT grew to ₹2,191 crores from ₹1,600 crores. Export revenue constituted 88% of sales, with Europe and the US contributing 73%. Product mix in Q4 was 49% Generic and 51% Custom Synthesis. Capitalized assets of ₹560 crores were added in the quarter, including ₹337 crores for the Kakinada project. Inventory stabilized near ₹3,033 crores despite record sales, reflecting lean sourcing efforts.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DIVISLAB ✨ Ask AI About This

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

💡 Ask AI about this filing

"How does this financial results affect Divi's Laboratories Limited's outlook?" "What did Divi's Laboratories Limited announce on 23 May 2025?" "Is this positive or negative for DIVISLAB?"

Ask AI Free →

📊 More DIVISLAB filings

See all DIVISLAB filings →

🔥 Also filed on 23 May 2025

SHRIRAMFIN Shriram Finance Limited Corporate Action SHRIRAMFIN Shriram Finance Limited Corporate Action SHRIRAMFIN Shriram Finance Limited Corporate Action TORNTPHARM Torrent Pharmaceuticals Limited Financial Results WIPRO Wipro Limited Annual Report BAJAJ-AUTO Bajaj Auto Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.